Probiotics for Kidney Health

Gut-Based Uremic Toxin Removal – "Enteric Dialysis™"

Natarajan Ranganathan, Ph.D. Kibow Biotech Inc., Newtown Square, PA
Eli A. Friedman, M.D. State University of New York, Brooklyn, NY

The 5th Asian Conference on Lactic Acid Bacteria
Microbes in Disease Prevention
1st to 3rd July 2009, Singapore



<u>Study Design: 6 months Double Blind Placebo Controlled Cross-over (after 3 months)</u>

Inclusion Criteria: CKD Stages III and IV, Scr > 2.5mg/ml, 18-75 yrs old

Study Site: Corp Med Ctr, Scarborough Hospital, Ontario, Canada.

Primary Endpoints: Biochemical (Urea, Creatinine, Uric acid) and CRP

Secondary Endpoints: Fecal Analysis and Quality of Life.

Results: 13 patients complete study.

Ave mean change: BUN: 4.52 mmol/L (placebo), -2.95mmol/L (KB), P = 0.002;
Uric acid: 50.62 µmol/L (placebo), 24.70 µmol/L (KB), P = 0.05, Scr: Stable,
CRP levels: Slightly lower,
Positive fecal changes observed with improved QOL (P = 0.05)

KIBOW®
Passionate about your health